KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to 0.16.

  • Alnylam Pharmaceuticals' Equity Ratio rose 90428.62% to 0.16 in Q4 2025 from the same period last year, while for Dec 2025 it was 0.16, marking a year-over-year increase of 90428.62%. This contributed to the annual value of 0.16 for FY2025, which is 90428.62% up from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Equity Ratio stood at 0.16 for Q4 2025, which was up 90428.62% from 0.05 recorded in Q3 2025.
  • Alnylam Pharmaceuticals' 5-year Equity Ratio high stood at 0.28 for Q1 2021, and its period low was 0.12 during Q2 2023.
  • Its 5-year average for Equity Ratio is 0.05, with a median of 0.02 in 2024.
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Equity Ratio crashed by 32693.53% in 2023 and then soared by 727494.72% in 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Equity Ratio (Quarter) stood at 0.16 in 2021, then crashed by 127.63% to 0.04 in 2022, then decreased by 29.13% to 0.06 in 2023, then surged by 127.46% to 0.02 in 2024, then skyrocketed by 904.29% to 0.16 in 2025.
  • Its Equity Ratio was 0.16 in Q4 2025, compared to 0.05 in Q3 2025 and 0.05 in Q2 2025.